Information on the following diseases can be found in the Related Disorders section of this report:

• hereditary non-polyposis colorectal cancer
• MHY-associated polyposis
• Peutz-Jeghers syndrome
• juvenile polyposis syndrome
• Cronkhite-Canada disease

Classic FAP is characterized by hundreds to thousand of colorectal adenomatous polyps, with polyps appearing on average at age 16 years. Without colectomy, affected individuals usually develop colorectal cancer by the third or forth decade of life. FAP is also associated with an increased risk for cancer of the small intestine (duodenum), thyroid, pancreas, liver (hepatoblatoma), central nervous system (CNS), and bile ducts, although these typically occur in less than 10% of affected individuals.

Individuals with CNS tumors and colorectal polyposis or cancer have historically been defined as Turcot syndrome. Two-thirds of cases of Turcot syndrome develop from mutations in the APC gene. The remaining cases of Turcot syndrome develop from mutations in the genes that cause hereditary non-polyposis colorectal cancer (HNPCC). Mutations in the APC gene are more commonly associated with medulloblastoma; mutations in the genes that cause HNPCC are more commonly associated with glioblastoma.

Extracolonic manifestations are variably present in FAP, including polyps of the gastric fundus and duodenum, osteomas (bony growths), dental abnormalities, congenital hypertrophy of the retinal pigment epithelium (CHRPE), and soft tissue tumors including epidermoid cysts, fibromas and desmoid tumors. About 5% of individuals with FAP experience morbidity and/or mortality from desmoid tumors. The term Gardner syndrome is often used when colonic polyposis is accompanied by osteomas and soft tissue tumors.

Attenuated FAP is a variant of familial adenomatous polyposis. The disorder is characterized by an increased risk for colorectal cancer but with fewer polyps (average of 30) and later age of onset than is typically seen in classic FAP. Extra-colonic manifestations are also associated with attenuated FAP.

Familial adenomatous polyposis is caused by germline mutations in the APC gene and is inherited as an autosomal dominant manner.

Dominant genetic disorders occur when only a single copy of an abnormal gene is necessary to cause a particular disease. The abnormal gene can be inherited from either parent or can be the result of a new mutation (gene change) in the affected individual. The risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy. The risk is the same for males and females.

Familial adenomatous polyposis affects males and females in equal numbers. It occurs in approximately one in 5,000 to 10,000 individuals in the United States and accounts for about 0.5% of all cases of colorectal cancer. One estimate suggests that familial adenomatous polyposis affects 50,000 American families. According to national registries, familial adenomatous polyposis occurs in 2.29-3.2 per 100,000 individuals.

Features of the following disorders can be similar to those of the APC-associated polyposis conditions. Comparisons may be useful for a differential diagnosis:

MYH-associated polyposis is an autosomal recessive cancer predisposition syndrome with a colonic phenotype similar to attenuated FAP. Mutations in the MYH gene are associated with this condition.

Hereditary non-polyposis colon cancer (HNPCC) is an autosomal dominant cancer predisposition syndrome that causes a very high risk for colorectal and endometrial cancer, in addition to an increased risk for cancers of the ovary, stomach, small intestine, hepatobiliary tract, upper urinary tract, brain, and skin. Due to the small number of polyps that occur in some individuals with HNPCC and attenuated FAP, differentiating between these two conditions may be difficult.

Peutz-Jeghers syndrome is an autosomal dominant genetic condition characterized by multiple benign hamartomatous polyps (Peutz-Jeghers polyps) in the gastrointestinal system. These polyps occur most often in the small intestine but also occur in the stomach and large intestine. Affected individuals also have dark skin discoloration which often presents in childhood and can be seen around the mouth, eyes, nostrils, mucous membranes of the mouth and perianal area. Affected individuals have an increased risk for intestinal and other cancers. (For more information on this disorder, choose "Peutz-Jeghers" as your search term in the Rare Disease Database.)

Juvenile polyposis syndrome (JPS) is an autosomal dominant genetic condition characterized by a predisposition to gastrointestinal polyps. The term "juvenile" refers to the type of polyp as opposed to the age of onset. Polyps are usually diagnosed by 20 years of age and are usually benign, although malignant transformation can occur. JPS is associated with mutations in the SMAD4 and BMPR1A genes.

Cronkhite-Canada disease is a very rare disease and is characterized by intestinal polyps, loss of taste and hair, and nail growth problems. It is difficult to treat because of malabsorption that accompanies the polyps. Cronkhite-Canada disease occurs primarily in older people (the average age is 59) and it is not believed to have a genetic component. There have been fewer than 400 cases reported in the past 50 years, primarily in Japan but also in the U.S. and other countries (For more information on this disorder, choose "Cronkhite-Canada" as your search term in the Rare Disease Database.)

Diagnosis
Classic FAP is diagnosed clinically when an individual has 100 or more adenomatous colorectal polyps (typically occurring by the third decade of life) or fewer than 100 polyps and a relative with FAP. Molecular genetic testing for mutations in the APC gene is available to confirm the diagnosis of FAP and the associated conditions. Younger individuals may have fewer polyps. A diagnosis is made in younger people by the presence of the typical polyps and in immediate relative with FAP or by genetic testing.

Treatment
Partial or complete removal of the colon (colectomy) is usually recommended for individuals with classical FAP. Sulindac is a nonsteroidal antiinflammatory drug (NSAID) that is sometimes prescribed for individuals with FAP who have had a colectomy to treat polyps in the remaining rectum.

Removal of duodenal polyps is sometimes recommended if they cause symptoms, are large or contain large numbers of abnormal cells (dysplasia).

Desmoid tumors may be treated with surgery, NSAIDs, anti-estrogen medications, chemotherapy and/or radiation.

Genetic counseling is recommended for individuals with familial adenomatous polyposis and their at-risk family members. Affected individuals should be screened regularly in order to identify cancerous and pre-cancerous tumors at an early stage.

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the National Institutes of Health (NIH) in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222
TTY: (866) 411-1010
Email: prpl@cc.nih.gov

Solomon C and Burt, R W. Updated 10/21/05. APC-Associated Polyposis Conditions. In: GeneReviews at Genetests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2008. Available at http://www.genetests.org. Accessed 5/08.

Lynch HT, Shaw TG, Lynch JF. Inherited predisposition to cancer: A historical overview. Am J Med Genet. 2004;15;129C(1):5-22.

National Cancer Institute: Genetics of Colorectal Cancer (http://www.cancer.gov/cancertopics/pdq/genetics/colorectal/HealthProfessional/page1)

Rowley PT. Inherited susceptibility to colorectal cancer. Annu Rev Med. 2005;56:539-54. Review.

Rustgi AK. The genetics of hereditary colon cancer. Genes Dev. 2007;15;21(20):2525-38. Review.

TEXTBOOKS
Beers MH, et al., eds. The Merck Manual. 17th ed. Whitehouse Station, NJ; Merck Research Laboratories; 1999:327-8.

Fauci AS, et al., eds. Harrison's Principles of Internal Medicine. 14th ed. New York, NY; McGraw-Hill Companies, Inc.; 1998:572-3.

Buyse ML. Birth Defects Encyclopedia. Dover, MA; Blackwell Scientific Publications, Inc.; 1990:983-6.

Sleisenger MH, et al. Gastrointestinal Disease. 4th ed. Philadelphia, PA; W.B. Saunders Company; 1989:1487-91, 1509-10.

Yamada T, et al. Textbook of Gastroenterology. 2nd ed. J.B. Lippincott Company; 1995:1944-54.

JOURNAL ARTICLES
van Stolk R, et al., Phase I trial of exisulind (sulindac sulfone, FGN-1 as a chemoprotective agent in patients with familial adenomatous polyposis. Clin Cancer Res. 2000;6:78-89.

Lal G, et al., Familial adenomatous polyposis. Semin Surg Oncol. 2000;18:314-23.

Gebert JF, et al. Combined molecular and clinical approaches for the identification of families with familial adenomatous polyposis coli. Ann Surg. 1999;229:350-361.

Berk T, et al. Negative genetic test result in familial adenomatous polyposis: clinical screening implications. Dis Colon Rectum. 1999;42:307-310.

Bonaiti-Pellie C, Genetic risk factors in colorectal cancer. Eur J Cancer Prev. 1999;9:S27-33.

Howe JR, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science. 1998;280:1086-1088.

Kinzler KW, et al. Landscaping the cancer terrain. Science. 1998;280:1036-1037.

Giardiello FM, et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med. 1997;336:823-827.

Winawer SJ, et al. Risk of colorectal cancer in the families of patients with adenomatous polyps. N Engl J Med. 1996;334:82-87.

Clark SK, et al., Desmoids in familial adenomatous polyposis. Br J Surg. 1996:83:1494-504.

Foulkes WD, A tale of four syndromes: familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome. QJM. 1995:88:853-63.

Tjandra JJ, et al. Similar functional results after restorative proctocolectomy in patients with familial adenomatous polyposis and mucosal ulcerative colitis. Am J Surg. 1993; 165:322-325.

Galandiuk S, et al. Expression of hormone receptors, cathepsin D, and HER-2/neu oncoprotein in normal colon and colonic disease. Arch Surg. 1993;128:637-642.

Penna C, et al. Function of ileal J pouch-anal anastomosis in patients with familial adenomatous polyposis. Br J Surg. 1993;80:765-767.

Burt RW, et al. Population genetics of colonic cancer. Cancer. 1992;70:1719-1722.

Rhodes M, et al. Overview of screening and management of familial adenomatous polyposis. Gut. 1992;33:125-131.

Konsker KA. Familial adenomatous polyposis: case report and review of extracolonic manifestations. Mt Sinai J Med. 1992;59:85-91.

Lynch HT, et al., Hereditary flat adenoma syndrome: a variant of familial adenomatous polyposis? Dis Colon Rectum. 1992;35:411-21.

Solomon C and Burt, R W. Updated 10/21/05. APC-Associated Polyposis Conditions. In: GeneReviews at Genetests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2008. Available at http://www.genetests.org. Accessed 5/08.

Lynch HT, Shaw TG, Lynch JF. Inherited predisposition to cancer: A historical overview. Am J Med Genet. 2004;15;129C(1):5-22.

National Cancer Institute: Genetics of Colorectal Cancer (http://www.cancer.gov/cancertopics/pdq/genetics/colorectal/HealthProfessional/page1)

Rowley PT. Inherited susceptibility to colorectal cancer. Annu Rev Med. 2005;56:539-54. Review.

Rustgi AK. The genetics of hereditary colon cancer. Genes Dev. 2007;15;21(20):2525-38. Review.